Loading

Journal of Pharmacology and Clinical Toxicology

Treating

Case Series | Open Access | Volume 6 | Issue 4

  • 1. Department of Medicine, University of The Andes, Venezuela
  • 2. Department of Physiology, University of The Andes, Venezuela
+ Show More - Show Less
Corresponding Authors
Ignacio Sandia S, UDA-Psiquiatría, Mezzanina, Hospital Universitario de Los Andes. Av. 16 de Septiembre. Mérida, 5101,Venezuela, Tel: 582403228//+584143742665
Abstract

We here report a series of six patients who were admitted at a hospital’s emergency room because of voluntary or involuntary intoxication with nonpharmaceutical scopolamine preparations known as ‘“Devil’s Breath”. Physostigmine, the antidote of choice in such cases, was not available at that institution. In four of these cases, psychotic symptoms did not improve after four days of treatment with appropriate doses of atypical antipsychotics (risperidone, olanzapine or quetiapine). The antipsychotic medication was then suspended in each case, and a transdermal patch of 10 cm2 of rivastigmine (equivalent to 9.5 mg of the drug) was indicated as monotherapy. The remaining two subjects did not receive any antipsychotic treatment but were administered rivastigmine immediately upon their arrival at the emergency room. Mental status was assessed with the Brief Psychiatric Rating Scale (BPRS) at baseline and on the third and fifth day. The BPRS scores significantly decreased when assessed on days 3 and 5 (p = 0.012). We argue that rivastigmine was pivotal in the fast and efficient resolution of these cases of intoxication with non-pharmaceutical scopolamine preparations.

Keywords

• Scopolamine hydrobromide

• Rivastigmine

• Antidotes

• Antipsychotics agents

• Brief psychiatric rating scale

• Emergency service hospital

Citation

Ignacio SS, Jorge RV, Javier PA, Trino BT (2018) Treating ‘Devil’s Breath’ Intoxication: Use of Rivastigmine in Six Patients with Toxic Psychoses Due to Non Pharmaceutical Scopolamine. J Pharmacol Clin Toxicol 6(4):1115.

INTRODUCTION

Scopolamine is a muscarinic antagonist widely known outside the scientific community as ‘Devil’s breath’ or ‘Burundanga’ (among other names) that denote its alkaloid cognitive inhibition properties when used for criminal purposes [1,2]. The botanical genres Datura and Brugmansia are the main natural suppliers of these highly toxic alkaloids [3], and poisoning with these plants is not uncommon [4].

Because of its anticholinergic power and parasympathetic activity, scopolamine has been found to be useful in clinical practice [5], and to be especially effective to prevent motion sickness [6]. It is moreover well known that the cholinergic hypofunction induced by scopolamine produces a loss of the emotional excitation stimulating effect in memory [7]. This seems to be the main effect sought out by criminals who have used preparations of the substance to commit various crimes in both Europe and the Americas [8,9] .

Scopolamine intoxication is characterized by being dosedependent with specific central and peripheral symptoms. Scopolamine causes a central and peripheral blockade of the muscarinic receptor causing restlessness, excitement,hallucinations, euphoria, and disorientation. Moreover, disturbances in level of consciousness at varying degrees and respiratory depression are not uncommon [10].

At proper doses physostigmine is, inter alia, the antidote of choice for scopolamine intoxication [11,12], but, because of the drug unavailability at the time of the study, the patients reported here --who had been intoxicated with non- pharmaceutical preparations of scopolamine--could not be treated with physostigmine.

Rivastigmine administration was decided because of its composition and properties similar to those of physostigmine [12,13]. Indeed, its combination with atypical antipsychotics has been well documented in the management of psychotic agitation in cases of dementia [14,15], but not in intoxication cases such as those reported here. Cases of scopolamine intoxications have been treated with other cholinesterase inhibitors, such as galantamine [16], and donezepil [17].

PATIENTS AND EXPERIMENTAL PROCEDURES

Six patients (all singles, 03 males, 03 females; aged: 17 ± 1,8 years) were admitted at the Emergency Unit of the University Hospital of The Andes (Mérida, Venezuela) because of an intoxication with non-pharmaceutical preparations of scopolamine. The emergency treatment -- which included general detoxification measures, an initial biomedical and psychosocial evaluation, and forced diuresis with matched hydration-- did not solve the psychiatric symptoms in spite of the fact that it improved the patients’ overall conditions, including the mixed alteration of their state of consciousness (lucidity, orientation and memory). Four of the patients were medicated with atypical antipsychotics for at least four days, but no therapeutic response was observed. The remaining two patients did not receive any antipsychotics. None of the patients presented Delirium due to scopolamine (mixed disturbance of consciousness) as it is described in the literature [5,18], and the psychotic symptoms were the main concern at the Emergency Unit. All the subjects were thus referred to the Psychiatric Emergency Unit of that same Institution. A before/after pre - experimental study was designed.

So as to discard kidney, liver or any other pathologies that could explain our patients’ symptomatology, the following laboratory tests were performed on the six subjects: red blood cell count, hemoglobin, hematocrit, white blood cell count and distribution, transaminase, creatinine, urea, baseline glycaemia, urinalysis and blood screening for marijuana, cocaine, opiates and benzodiazepines metabolites. No patient presented respiratory depression, stupor or coma, and all of them were treated according to the treatment guidelines of the University Hospital of the Andes Psychiatry Unit.

Laboratory values of the substance were not determined. However, it is well known that urine concentrations of scopolamine may range from 32.4 to 186.4 ng /mL in cases of intoxication due to the ingestion of plants containing the substance [4]. Moreover, a series of scopolamine-facilitated robberies reported a concentration of scopolamine in blood of 0.30mg/L, about 3000 times higher than the average therapeutic level of 0.0001mg/L [19].

Once the protocol was accepted, the antipsychotic medication was suspended (when applicable), and the six patients were treated once daily and for five days with 10cm2 transdermal patches equivalent to 9.5 mg of rivastigmine.

Following the Ethics Committee of the University Hospital of The Andes recommendations and the Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects (WMA 2015), all the patients and/or their legal representatives were informed about the aspects related to this research, including the protocol, risks, goals, confidentiality, and access to the research results,

The level of psychopathology was assessed with the Brief Psychiatric Rating Scale (BPRS) of 18 items quantified with a Likert scale of 1-7 [20]. In the present study, a validated version for the Spanish language was used [21]. The total score has a maximum of 126 points; the subscales of positive and negative symptoms (each one with 4 items) have a maximum score of 28 points. The BPRS scale was applied on the first, third and fifth day of treatment.

The SPSS statistical package, version 22, was used to organize the data obtained. The BPRS score at baseline and throughout the treatment was analyzed using Friedman’s non-parametric tests as well as the Wilcoxon Sign rank test for comparison of specific treatment intervals. Statistical significance was set at p <0.05.

RESULTS

In these subjects, the scopolamine route of entry to the organism was either involuntary (the patient had been a victim of premeditated poisoning) or voluntary since it is well known that the substance can also be used for fun or in canonical ceremonies. In all six cases, the scopolamine preparations had no authorized pharmaceutical origin and their form of preparation was unknown, although the literature reports cases of extraction from over the counter preparations [22], or as botanical extractions [23].

The six subjects were adolescents and single. Five (83 %) were unemployed. The sex distribution was uniform, and in 50% of the cases the use of scopolamine was involuntary. Of the six subjects, two did not receive any antipsychotic medication, two were administered risperidone (2-6mg / day), one was given olanzapine (10-20mg/day), and another one received a combination of quetiapine (200-300 mg/day) plus risperidone (2-6 mg/day).

Before starting the treatment with rivastigmine (baseline conditions), the score on positive symptoms was much higher than that on negative symptoms: 23.8 ± 1.6 vs. 15.3 ± 2.5, Mann-Whitney U test, z = 2.9, p = 0.004. This may be a pointer of the clinical picture of this type of intoxication. Treatment with rivastigmine was associated with a significant decrease in the overall score (p=0.002) and in the subscales for positive and negative symptoms (p = 0.003 for both type of symptoms) (Figure 1).

Friedman test: ?2  (2) = 12.0, p = 0.002; Wilcoxon test: basal vs. day  3: Z = 2.2, p = 0.028; basal vs. day 5 and day 3 vs. day 5: Z = 2.1, p =  0.019. (B) Friedman test: ?2  (2) = 11.6, p = 0.003: Wilcoxon test: basal vs.  day 3: Z = 2.2, p = 0.027; basal vs. day 5: Z = 2.1, p = 0.026; day 3 vs.  day 5 = 2.0, p = 0.039.  (C) Friedman test: ?2  (2) = 11.5, p = 0.003: Wilcoxon test: basal vs. day  3: Z = 2.2, p = 0.026; basal vs. day 5: Z = 2.2, p = 0.028; day 3 vs. day  5 = 2.0, p = 0.04.

Figure 1 (A) Friedman test: χ2 (2) = 12.0, p = 0.002; Wilcoxon test: basal vs. day 3: Z = 2.2, p = 0.028; basal vs. day 5 and day 3 vs. day 5: Z = 2.1, p = 0.019. (B) Friedman test: χ2 (2) = 11.6, p = 0.003: Wilcoxon test: basal vs. day 3: Z = 2.2, p = 0.027; basal vs. day 5: Z = 2.1, p = 0.026; day 3 vs. day 5 = 2.0, p = 0.039. (C) Friedman test: χ2 (2) = 11.5, p = 0.003: Wilcoxon test: basal vs. day 3: Z = 2.2, p = 0.026; basal vs. day 5: Z = 2.2, p = 0.028; day 3 vs. day 5 = 2.0, p = 0.04.

On the following items of the scale, no significant decrease was detected in the individual scores: basal vs. day 3: items 1 (somatic concern), 5 (self-deprecation and feelings of guilt), 6 (somatic tension / anxiety), 7 (mannerisms and strange postures) and 9 (depressive mood); basal vs. day 5: items 5 and 16 (dulling / affective flattening).

DISCUSSION

The present study demonstrates the clinical effectiveness of transdermal patches of rivastigmine in the treatment of non-pharmacological scopolamine intoxication. This is an encouraging finding that will help improve the treatment of a medically unrecognized intoxication with psychiatric symptoms that is often reported in the media [23-25].

The beneficial effect of transdermal rivastigmine patches was evident both on the global BPRS scale and on the subscales for positive and negative symptoms. It is important to emphasize that the beneficial effect was greater on the positive than on the negative symptoms, which allows a better clinical characterization of the psychopathological effects of nonpharmacological scopolamine.

The improvement of the psychotic symptoms in the six cases reported here could be explained by the fact that the majority of our patients had received antipsychotics prior to the administration of rivastigmine. However, previous research has shown that the mechanism by which psychotic symptoms occur in scopolamine intoxication is due to the drug antimuscarinic effects, and that when those symptoms are treated with antipsychotics, the response is not the expected one unless a cholinesterase inhibitor is added [26,27].

Although the ratio response of scopolamine-rivastigmine has already been tested in experimental animals [28], the present study is the first to suggest that rivastigmine without antipsychotics could be effective in this type of intoxications in humans.

We argue that the improvement in psychotic symptoms (as revealed by the BPRS overall and sub-scale results) can only be explained by the beneficial effect of the transdermal patches of rivastigmine since it is the only pharmacological variable introduced in the treatment, especially in the four subjects who did not respond to antipsychotics for over 72 hours.

It is well known that the addition of cholinesterase inhibitors to antipsychotics improves symptoms [14], but not under the circumstances reported here where the muscarinic antagonistic properties of the antipsychotic would have accentuated the anticholinergic symptoms produced by scopolamine poisoning. It is worthwhile emphasizing that the response to the transdermal patches of rivastigmine was identical in the two cases where no atypical antipsychotic was prescribed.

It could be argued that, since our six subjects were young and healthy, their improvement was due to the substance elimination. However, because the metabolism of scopolamine can take up to 108 hours [5,29], our patients’ improvement can only be explained by the therapeutic effect of rivastigmine.

It should finally be emphasized that our patients’ improvement was similar for the subjects who were given the transdermal patch several days after their arrival at the Hospital Emergency Unit as for those who were immediately given the patch upon admission. As we stated before, previous research on animal models has shown that rivastigmine reverts the cognitive effects of scopolamine [30-32], but we would like to suggest here that rivastigmine could also reverse psychiatric symptoms induced by scopolamine intoxication.

Given the efficacy of rivastigmine transdermal patches and its ease of administration, further research should be conducted on larger samples of patients. Additional research should also aim to compare the efficacy of rivastigmine vs that of physostigmine and to determine rivastigmine response time course.

AUTHOR DISCLOSURE

Role of funding source

There was no Funding for this study other than the University Hospital of the Andes (IAHULA) resources; the IAHULA had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Contributors

Ignacio Sandia, Jorge Ramirez and Javier Piñero designed the study and wrote the protocol. Jorge Ramirez and Javier Piñero collected the data. Jorge Ramirez and Ignacio Sandia managed the literature searches and analyses. Trino Baptista the statistical analysis, Ignacio Sandia wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.

ACKNOWLEDGEMENTS

We are most grateful to our patients and their relatives for their cooperation, and to Françoise Meyer our trained scientific editor.

• 9. HighlightsScopolamine preparations known as Devil’s Breath are reportedly used by criminals.

• An approach to the psychopathological effects of nonpharmacological scopolamine.

• A treatment for a medically unrecognized intoxication often reported in the media.

• Rivastigmine alone might reverse psychiatric symptoms induced by scopolamine.

REFERENCES

1. Stebner B. The most dangerous drug in the world: ‘Devil’s Breath’ chemical from Colombia can block free will, wipe memory and even kill. The Daily Mail. 2012.

2. Damin C. Qué es y cómo actúa la Escopolamina, “Burundanga”. 2015.

3. Alvarez L. Borrachero, cacao sabanero o floripondio (brugmansiaspp.). Un grupo de plantas por redescubrir en la biodiversidad latinoamericana. Cultura y Droga. 2008; 13: 77-93.

4. Papoutsis I, Nikolaou P, Athanaselis S, Stefanidou M, Pistos C, Spiliopoulou C, Maravelias, et al. Mass intoxication with Datura innoxia--case series and confirmation by analytical toxicology. C. ClinToxicol (Phila). 2010; 48: 143-145.

5. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther Drug Monit. 2005; 27: 655-665.

6. Brainard A, Gresham C. Prevention and Treatment of Motion Sickness. Am Fam Physician. 2014; 90: 41-46.

7. Kamboj SK, Curran HV. Neutral and emotional episodic memory: global impairment after lorazepam or scopolamine. Psychopharmacol (Berl). 2006; 188: 482-488.

8. Peatfield, Villalón. Headache after exposure to ‘date-rape’ drugs. Springer Plus. 2013; 2: 39.

9. Draper L. Does the “Devil’s Breath” Drug Really Exist? Newsweek. Europe Edition. 2015.

10. Apfel C, Zhang K, George E, Shi S, Jalota L, Hornuss C, et al. Transdermal scopolamine for the prevention of postoperative nausea and vomiting: a systematic review and meta-analysis. ClinTher. 2010; 32: 2502.

11. Gómez CU. Escopolamina, in: Ministerio de la protección Social (Eds.) Guías para el manejo de urgencias toxicológicas. Chapter 3.7 Bogotá, Colombia: Imprenta Nacional de Colombia; 2008.

12. Barak D, Ordentlich A, Stein D, Yu Q, Greig N, Shafferman A. Accommodation of physostigmine and its analogs by acetylcholinesterase is dominated by hydrophobic interactions. Biochem J. 2009; 417: 213-222.

13. Buccafusco J. The Revival of Scopolamine Reversal for the Assessment of Cognition-Enhancing Drugs, in: Buccafusco JJ (Ed) Methods of Behavior Analysis in Neuroscience Chapter 17. Boca Raton (FL): CRC Press/Taylor & Francis. 2009.

14. Holmes C, Wilkinson D, Dean C, Clare C, El-Okl M, Hensford C, et al. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer’s disease: a randomised double blind placebo controlled study. Int J Geriatr Psychiatry. 2007; 22: 380-381.

15. Rocca P, Marino F, Montemagni C, Perrone D, Bogetto F. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer’s disease: preliminary findings from a naturalistic, retrospective study. Psychiatry Clin Neurosci. 2007; 61: 622-629.

16. Cozanitis DA. Galanthaminehydrobromide, a longer acting anticholinesterase drug, in the treatment of the central effects of scopolamine (Hyoscine). Anaesthesist. 1977; 26: 649-650.

17. Snyder PJ, Bednar M, Cromer JR, Maruff P. Reversal of scopolamineinduced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor. Alzheimer’s Dement. 2005; 1: 126-135.

18. Corallo CE, Whitfield A, Wu A. Anticholinergic syndrome following an unintentional overdose of scopolamine.Ther Clin Risk Manag. 2009; 5: 719-723.

19. Lusthof K, Bosman I, Kubat B, Vincenten-van Maanen M. Toxicological results in a fatal and two non-fatal cases of scopolamine-facilitated robberies. Forensic Sci Int. 2017; 274: 79-82.

20. Overall, John E, Gorham, Donald R. The Brief Psychiatric Rating Scale. Psychological Reports. 1962; 10: 799-812.

21. Sánchez R, Ibáñez MA, Pinzón A. Análisis factorial y validación de la versión en español de la escala Brief Psychiatric Rating Scale en Colombia. Biomédica. 2005; 25: 120-128.

22. Kummer S, Rickert A, Daldrup T, Mayatepek E. Abuse of the over-thecounter antispasmodic butylscopolamine for the home synthesis of psychoactive scopolamine.Eur J Pediatr. 2015; 175: 1019-1021.

23. Bernal A, Gómez López S, Acosta M. Neuropsychological, neurological and psychiatric implications in a case of poisoning scopolamine. Universidad de San Buenaventura, Bogotá – Colombia. Psychol Av Discip. 2013.

24. Lares V. Venezuela: alerta por burundanga. Diario El Tiempo. 2006.

25. Samuel, Henry. Three arrested in Paris over ‘devil’s breath’ drug that turns victims into willing ‘zombies’ The Telegraph News. 2015.

26. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology. 1995; 12: 3-16.

27. Barak S, Weiner I. Scopolamine Induces Disruption of Latent Inhibition which is prevented by Antipsychotic Drugs and an Acetylcholinesterase Inhibitor. Neuropsychopharmacology. 2007; 32: 989-999.

28. Bejar C, Wang R, Weinstock M. Effect of rivastigmine on scopolamineinduced memory impairment in rats.Eur J Pharmacol. 1999; 383: 231- 240.

29. TOXNET Hazardous Substances Data Bank [Internet]. Bethesda (MD): National Library of Medicine (US); (Last Revision Date 2009); Scopolamine CASRN: 51-34-3; Hazardous Substances Databank Number: 4074.

30. Deiana S, Harrington CR, Wischik CM, Riedel G. Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl). 2009; 202: 53-65.

31. Müller J, Wanke K. Toxic psychoses from atropine and scopolamine. Fortschr Neurol Psychiatr. 1998; 66 : 289-295.

32. Le Garff E, Delannoy Y, Mesli V, Hédouin V, Tournel G. Forensic features of a fatal Datura poisoning case during a robbery. Forensic Sci Int. 2016; 261: e17-21.

Ignacio SS, Jorge RV, Javier PA, Trino BT (2018) Treating ‘Devil’s Breath’ Intoxication: Use of Rivastigmine in Six Patients with Toxic Psychoses Due to Non Pharmaceutical Scopolamine. J Pharmacol Clin Toxicol 6(4).

Received : 20 Jul 2018
Accepted : 30 Jul 2018
Published : 31 Jul 2018
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X